Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,201
datasets available to search
ShareScore release 0.9.0
Dataset results
1,201 results for “oncology”
Combined immune checkpoint blockade increases myocardial secretion of H-FABP, NT-Pro-BNP, NLRP-3 inflammasome, Interleukin-1β and Interleukin-6: biochemical implications in cardio-immuno-oncology
<p>Background: Immune checkpoint inhibitors have transformed the treatment of several cancers by releasing restrained antitumor immune responses. Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody, and nivolumab, an anti–programmed death-1 (PD-1) antibody, have individually improved survival in patients with melanoma, and their combination further enhances antitumor activity and survival. More recently, an anti-LAG3 human monoclonal antibody, Relatlimab, has been approved by FDA for combinatorial treatment with Nivolumab for metastatic melanoma and an anti-PD-L1 mAb,Atezolizumab, is undergoing clinical trials evaluation in combination with Ipilimumab for metastatic lung cancer.However,adverse events associated with these agents include dermatitis, endocrinopathies, colitis, hepatitis, and pneumonitis, which are all thought to arise from aberrant activation of autoreactive T cells. These toxic effects are more frequent and severe when immunomodulatory mAbs are used in combination. </p> <p>Methods: human cardiomyocytes co-cultured with hPBMC were exposed to monotherapy and combinatorial ICIs (PD-L1 and CTLA-4 or PD-1 and LAG-3 blocking agents, at 200 nM) for 48 h. After treatments, cardiac cell lysis and secretion of biomarkers of cardiotoxicity (H-FABP, NT-Pro-BNP), NLRP3-inflammasome and Interleukin 1 and 6 were determined through colorimetric and enzymatic assays. <strong>Results:</strong>Both Combinations of immune checkpoint inhibitors exertmore potent cardiotoxic side effects compared to monotherapies against human cardiac cells co-cultured with human lymphocytes. LDH release from cardiac cells was 43% higher in PDL-1/CTLA-4 blocking agents, and 35.7% higher in PD-1/LAG-3 blocking agents compared to monotherapies. Biomarkers of cardiotoxicity, such as H-FABP and NT-Pro-BNP were also strongly increased in combination therapy than monotherapies. NLRP3 inflammasome, IL-1β and IL-6 levels were also increased by PDL-1/CTLA-4 and PD-1/LAG-3 combined blocking agents compared to untreated cells and monotherapies. </p> <p><strong>Conclusions:</strong>Data of the present study, although in vitro, indicate that combinatorial immune checkpoint blockade on co-cultures of hPBMCs and cardiac cells, including for the first time the anti LAG-3 monoclonal antibody, induce a pro- inflammatory phenotype, thus indicating that these therapies should be closely monitored by the multidisciplinary team consisting of oncologists, cardiologists and immunologists.</p>
Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology
ClinicalTrials.gov study NCT00646945. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology
ClinicalTrials.gov study NCT04758442. IPD Sharing: UNDECIDED. Countries: 1. Publications: 16.
Predictive Factors for Postoperative Pain, Nausea and Vomiting in Oncological Patients
ClinicalTrials.gov study NCT04889534. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials
ClinicalTrials.gov study NCT02948413. IPD Sharing: Not stated. Countries: 1. Publications: 3.
The Treatment of Addictions in the Course of Care in Oncology: an Inventory of Fixtures Among Paramedical Professionals
ClinicalTrials.gov study NCT03706937. IPD Sharing: NO. Countries: 1. Publications: 1.
NMR Metabolomics Study of Follicular Fluid of Oncological Patients
ClinicalTrials.gov study NCT04101981. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase
ClinicalTrials.gov study NCT00001217. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent
ClinicalTrials.gov study NCT06815120. IPD Sharing: UNDECIDED. Countries: 0. Publications: 15.
Database for Data Collection in the Context of an Enhanced Recovery After Surgery Program in Oncology Surgery
ClinicalTrials.gov study NCT03950011. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Postoperative Cognitive Dysfunction in Elderly Urologic Oncology Patients (POCD)
ClinicalTrials.gov study NCT04837391. IPD Sharing: NO. Countries: 1. Publications: 6.
Copenhagen Prospective Personalized Oncology (CoPPO)
ClinicalTrials.gov study NCT02290522. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Polaris Oncology Survivor Transition (POST) System
ClinicalTrials.gov study NCT02637349. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Ultrasound Use for Difficult Lumbar Punctures in Pediatric Oncology Patients
ClinicalTrials.gov study NCT01643291. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Evaluating the Impact of an Integrative Oncology Training Program for Healthcare Providers
ClinicalTrials.gov study NCT06598020. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Medication Reconciliation in Oncologic Patients
ClinicalTrials.gov study NCT04796142. IPD Sharing: NO. Countries: 1. Publications: 1.
Prehabilitation Plus ERAS Versus ERAS in Gynecologic Oncology: a Randomized Clinical Trial
ClinicalTrials.gov study NCT04596800. IPD Sharing: YES. Countries: 1. Publications: 10.
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
ClinicalTrials.gov study NCT04957160. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PICC-ports Versus Chest - Ports for Long Term Chemotherapy Deliverance in Oncology Patients
ClinicalTrials.gov study NCT06541301. IPD Sharing: Not stated. Countries: 1. Publications: 10.
A Nurse-led Multicomponent Interventional Protocol to Improve Sleep Quality in Paediatric Oncology Patients
ClinicalTrials.gov study NCT07323069. IPD Sharing: NO. Countries: 1. Publications: 16.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.